

Examples of compulsory licensing for pharmaceuticals worldwide

Year	Country	Products	Type	Results
2002	Zimbabwe	Any drug used for the treatment of HIV/AIDS	Emergency	The average price of ARVs dropped from \$30 to \$50 per month to just over \$15 a month, cutting the price by at least 50%.
2003	Malaysia	3 ARVs: ddl; AZT; 3TC + AZT (Combivir)	Govt use	Average cost reduction of about 81% per patient per month; number of patients treated by public services increased from 1,500 to 4,000.
2004	Mozambique	3 ARVs: 3TC; d4T; and NVP	Extreme Emergency	
2004	Zambia	ARV: 3TC + d4T + AZT	Extreme Emergency	
2004, 2007, 2012	Indonesia	2004—2 ARVs: NVP; 3TC 2007—3 ARVs: NVP; 3TC; and EVF 2012—Seven ARVs + Hep B: EVF; ABC; ddl; LPV/RTV; TDF; TDF+ FTC; and TDF+ FTC+ EFV	Govt use	About 2000 patients received free access to ARVs after first two licenses.
2005	Eritrea	ARVs	Emergency, Govt use	
2005	Ghana	ARVs	Emergency, Govt use	Annual price for ARVs dropped by 50%.
2005, 2006, 2007	Italy	2005—antibiotic combination: imipenem+cilastatin 2006—migraine drug: sumatriptan succinate 2007—prostate cancer: finasteride, a treatment for prostate hypertrophy, prostate cancer and male baldness	Anti- competitive practices	
2006, 2007, 2008	Thailand	2006—1 ARV: EFV 2007—2 ARVs + cardiovascular: LPV/RTV; and clopidogrel 2008—cancer treatments: docetaxel; erlotinib; letrozol; imatinib (ultimately the imatinib CL was not needed due to the successful negotiations with patent holders)	Govt use	The price of EFV was reduced by seven times; LPV/RTV by 75%; clopidogrel by 91%; docetaxel by 24 times; letrozol by 70 times. After the CL, Abbott cut the price of lpv/r by more than 55% for over 40 countries for low and middle-income countries. Patients accessing LPV/r tripled in 2008. By 2010, the number of patients receiving EFV increased from 4,539 to 29,360 in Thailand.
2007	Brazil	EFV	Govt use	CL produced immediate savings of US\$31.5 million.
2009, 2010, 2012	Ecuador	2010—ARV: RTV 2012—ARV: ABC+3TC		30% reduced price offer for ritonavir
2012	India	Sorafenib (drug against kidney and liver cancer)		It is estimated that the price of the drugs will be reduced by 97% from US\$5,500 to US\$ 175 per patient per month.

Legend: 3TC= lamivudine / ABC= abacavir / AZT= zidovudine / d4t= stavudine / ddl= didanosine / EVF= efavirenz / FTC= emtricitabine / LPV= lopinavir / NVP= nevirapine / RTV= ritonavir / TDF= tenofovir



**Public Citizen's Global
Access to Medicines Program**

Website:
www.citizen.org/access

Email:
medsaccess@citizen.org

Twitter:
[@PCMedsAccess](https://twitter.com/PCMedsAccess)

Examples of compulsory licensing for pharmaceuticals worldwide

Legend: 3TC= lamivudine / ABC= abacavir / AZT= zivoduvine / d4t= stavudine / ddl= didanosine / EVF= efavirenz / FTC= emtricitabine / LPV= lopinavir / NVP= nevirapine / RTV= ritonavir / TDF= tenofovir



**Public Citizen's Global
Access to Medicines Program**

Website:
www.citizen.org/access

Email:
medsaccess@citizen.org

Twitter:
[@PCMedsAccess](https://twitter.com/PCMedsAccess)